OMEROS CORP (OMER) Stock Fundamental Analysis
NASDAQ:OMER - Nasdaq - US6821431029 - Common Stock - Currency: USD
We assign a fundamental rating of 2 out of 10 to OMER. OMER was compared to 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of OMER have multiple concerns. OMER does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year OMER has reported negative net income.
OMER had a positive operating cash flow in the past year.
In multiple years OMER reported negative net income over the last 5 years.
In the past 5 years OMER reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -56.60%, OMER is doing worse than 63.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -56.6% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)7.74%
ROA(5y)-22.95%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for OMER so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for OMER has been reduced compared to 1 year ago.
OMER has more shares outstanding than it did 5 years ago.
OMER has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -6.09, we must say that OMER is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -6.09, OMER is not doing good in the industry: 65.66% of the companies in the same industry are doing better.
The Debt to FCF ratio of OMER is 5.46, which is a neutral value as it means it would take OMER, 5.46 years of fcf income to pay off all of its debts.
OMER has a Debt to FCF ratio of 5.46. This is amongst the best in the industry. OMER outperforms 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 5.46 | ||
| Altman-Z | -6.09 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
OMER has a Current Ratio of 1.69. This is a normal value and indicates that OMER is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.69, OMER is doing worse than 66.67% of the companies in the same industry.
OMER has a Quick Ratio of 1.69. This is a normal value and indicates that OMER is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.69, OMER is doing worse than 60.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.69 | ||
| Quick Ratio | 1.69 |
3. Growth
3.1 Past
OMER shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -43.62%.
EPS 1Y (TTM)-43.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-260%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, OMER will show a very strong growth in Earnings Per Share. The EPS will grow by 32.45% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y18.65%
EPS Next 2Y41.78%
EPS Next 3Y30.01%
EPS Next 5Y32.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
OMER reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OMER is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
98.48% of the companies in the same industry are more expensive than OMER, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.97 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as OMER's earnings are expected to grow with 30.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.78%
EPS Next 3Y30.01%
5. Dividend
5.1 Amount
OMER does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.795
-2.38 (-38.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners46.12%
Inst Owner Change0.62%
Ins Owners4.42%
Ins Owner Change0%
Market Cap220.34M
Analysts80
Price Target41.31 (988.54%)
Short Float %16.52%
Short Ratio11.52
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.93%
Min EPS beat(2)21.96%
Max EPS beat(2)31.91%
EPS beat(4)3
Avg EPS beat(4)15.96%
Min EPS beat(4)-6.37%
Max EPS beat(4)31.91%
EPS beat(8)6
Avg EPS beat(8)18.19%
EPS beat(12)10
Avg EPS beat(12)58.71%
EPS beat(16)13
Avg EPS beat(16)47.33%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-3.99%
EPS NY rev (3m)-3.99%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | 2.97 | ||
| P/OCF | 2.95 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.7
EYN/A
EPS(NY)-2.2
Fwd EYN/A
FCF(TTM)1.28
FCFY33.72%
OCF(TTM)1.29
OCFY33.91%
SpS0
BVpS-3.15
TBVpS-3.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -56.6% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)7.74%
ROA(5y)-22.95%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 5.46 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 46.3% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.69 | ||
| Quick Ratio | 1.69 | ||
| Altman-Z | -6.09 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)26.05%
Cap/Depr(5y)22.78%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-260%
EPS Next Y18.65%
EPS Next 2Y41.78%
EPS Next 3Y30.01%
EPS Next 5Y32.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year69.65%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y185.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y186.41%
OCF growth 3YN/A
OCF growth 5YN/A